StreetInsider.com News Articles

Form 4 Artiva Biotherapeutics, For: Oct 06 Filed by: Aslan Fred

Wed, 07 Oct 2026 16:02:00 -0400

si-local-file:///var/storage/secattach/20261007/27161179.html

Form 144 Artiva Biotherapeutics, Filed by: Aslan Fred

Tue, 06 Oct 2026 16:22:00 -0400

si-local-file:///var/storage/secattach/20261006/27155796.html

Form 4 Artiva Biotherapeutics, For: Oct 05 Filed by: Horan Christopher

Tue, 06 Oct 2026 16:03:00 -0400

si-local-file:///var/storage/secattach/20261006/27155370.html

Form 4 Artiva Biotherapeutics, For: Oct 05 Filed by: Banerjee Subhashis

Tue, 06 Oct 2026 16:02:00 -0400

si-local-file:///var/storage/secattach/20261006/27155357.html

Form 4 Artiva Biotherapeutics, For: Oct 05 Filed by: Bush Jennifer

Tue, 06 Oct 2026 16:02:00 -0400

si-local-file:///var/storage/secattach/20261006/27155359.html

Form 4 Artiva Biotherapeutics, For: Oct 05 Filed by: Aslan Fred

Tue, 06 Oct 2026 16:01:00 -0400

si-local-file:///var/storage/secattach/20261006/27155352.html

Artiva Biotherapeutics to present AlloNK data at ACR 2026

Fri, 02 Oct 2026 09:05:26 -0400

Artiva Biotherapeutics, Inc. (Nasdaq: ARTV) announced it will present one oral presentation and two poster presentations at ACR Convergence 2026, taking place November 6–11, 2026, at the Orange County Convention Center in Orlando, Florida.

The oral presentation will feature updated clinical data from at least 20 patients with refractory rheumatoid arthritis (RA), 11 patients with Sjögren disease, and at least five patients with systemic sclerosis treated with AlloNK plus rituximab in an ongoing Phase 2a basket trial, all with at least six months of follow-up.

One poster presentation will highlight B-cell depletion data and tolerability findings across immune-mediated diseases from a cohort

Artiva Biotherapeutics Announces Multiple AlloNK® Data Presentations at the American College of Rheumatology (ACR) Convergence 2026

Fri, 02 Oct 2026 09:05:00 -0400

Oral presentation highlighting updated clinical data from at least 20 patients with refractory rheumatoid arthritis (RA), 11 patients with Sjögren disease (SjD) and at least five patients with systemic sclerosis (SSc) treated with AlloNK plus rituximab in the ongoing Phase 2a basket trial, all with at least six months of follow-up
Poster presentation highlighting deep, consistent B-cell depletion comparable to that observed with CD19 CAR T-cell therapies and a favorable tolerability profile across immune-mediated diseases
Poster presentation characterizing the high unmet medical need and low clinical response rates among patients with refractory RA following an inadequate response to at

Artiva Biotherapeutics Announces Multiple AlloNK® Data Presentations at the American College of Rheumatology (ACR) Convergence 2026

Fri, 02 Oct 2026 09:05:00 -0400

Oral presentation highlighting updated clinical data from at least 20 patients with refractory rheumatoid arthritis (RA), 11 patients with Sjögren disease (SjD) and at least five patients with systemic sclerosis (SSc) treated with AlloNK plus rituximab in the ongoing Phase 2a basket trial, all with at least six months of follow-up
Poster presentation highlighting deep, consistent B-cell depletion comparable to that observed with CD19 CAR T-cell therapies and a favorable tolerability profile across immune-mediated diseases
Poster presentation characterizing the high unmet medical need and low clinical response rates among patients with refractory RA following an inadequate response to at

Artiva Biotherapeutics (ARTV) Reiterated at Overweight by Cantor Fitzgerald on P1/2 AlloNK Data

Fri, 02 Oct 2026 07:05:12 -0400

Cantor Fitzgerald analyst Josh Schimmer reiterated an Overweight rating and $40.00 price target on Artiva Biotherapeutics (NASDAQ: ARTV).
The analyst commented, "This morning, ARTV presented updated P1/2 AlloNK data in 11 refractory, severe Sjögren's disease (SjD) patients at the International Symposium on Sjögren's Disease (ISSjD). While investor focus has primarily centered on AlloNK’s application in RA, we believe the opportunity in Sjögren's remains underappreciated, with encouraging early efficacy in another large indication with significant unmet need. Recall, initial SjD data shared in May from the broader autoimmune basket trial (n=7) showed encouraging activity across measures of disease activity and symptom burden,

H.C. Wainwright Reiterates Buy Rating on Artiva Biotherapeutics (ARTV)

Fri, 02 Oct 2026 07:00:21 -0400

H.C. Wainwright analyst Emily Bodnar reiterated a Buy rating and $35.00 price target on Artiva Biotherapeutics (NASDAQ: ARTV).
The analyst commented: "This morning, Artiva announced it has presented an oral presentation at the International Symposium of Sjögren’s Disease (ISSjD 2026) which included an update on the first 11 patients with SjD treated with AlloNK + RTX who have reached 6+ months of follow up by data-cut off of July 2, 2026. We remind investors that at EULAR, there were 7 patients who had reached 6+ months of follow up; therefore, this update includes 4 more patients worth of data. The company

Artiva shares AlloNK data in Sjögren disease at Paris symposium

Thu, 01 Oct 2026 07:31:35 -0400

Artiva Biotherapeutics (Nasdaq: ARTV) presented updated clinical data for its AlloNK therapy in combination with rituximab at the 17th International Symposium on Sjögren's Disease (ISSjD 2026) in Paris, according to a company statement.
The oral presentation covered data from 11 patients with Sjögren disease enrolled in Artiva's Phase 2a basket trial, all of whom had at least six months of follow-up as of a July 2, 2026 data cutoff. All 11 patients were women with a mean disease duration of 12.2 years who had not responded adequately to prior standard therapies.
At six months, mean ClinESSDAI, a measure of systemic disease activity,

Artiva Biotherapeutics Highlights Updated AlloNK® Data in Sjögren Disease Presented at the 17th International Symposium on Sjögren’s Disease (ISSjD 2026)

Thu, 01 Oct 2026 07:30:00 -0400

Oral presentation includes safety and efficacy data as of the July 2, 2026 data cutoff, highlighting clinically meaningful improvements in disease activity and symptoms at six months in 11 patients with longstanding, highly active Sjögren disease

Mean stimulated salivary flow increased from 0.4 to 1.1 mL/min among eight patients with baseline hyposalivation and available six-month data

Updated safety data across 73 Phase 2a basket study patients support the potential for outpatient administration, with no cytokine release syndrome, ICANS or treatment discontinuations due to adverse events

SAN DIEGO, Oct. 01, 2026 (GLOBE NEWSWIRE)

Artiva Biotherapeutics Highlights Updated AlloNK® Data in Sjögren Disease Presented at the 17th International Symposium on Sjögren’s Disease (ISSjD 2026)

Thu, 01 Oct 2026 07:30:00 -0400

Oral presentation includes safety and efficacy data as of the July 2, 2026 data cutoff, highlighting clinically meaningful improvements in disease activity and symptoms at six months in 11 patients with longstanding, highly active Sjögren disease

Mean stimulated salivary flow increased from 0.4 to 1.1 mL/min among eight patients with baseline hyposalivation and available six-month data

Updated safety data across 73 Phase 2a basket study patients support the potential for outpatient administration, with no cytokine release syndrome, ICANS or treatment discontinuations due to adverse events

SAN DIEGO, Oct. 01, 2026 (GLOBE NEWSWIRE)

Artiva Biotherapeutics Announces Oral Presentation of AlloNK® Clinical Data at the 17th International Symposium on Sjögren’s Disease

Wed, 23 Sep 2026 07:30:00 -0400

Oral presentation to highlight updated clinical data from 11 patients with Sjögren disease (SjD) treated with AlloNK and rituximab, with six months or more of follow-up
SAN DIEGO, Sept. 23, 2026 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (Nasdaq: ARTV) (Artiva), a clinical-stage biotechnology company whose mission is to develop effective, safe and accessible cell therapies for patients with debilitating autoimmune diseases, today announced that updated clinical data will be delivered in an oral presentation at the 17th International Symposium on Sjögren’s Disease (ISSjD 2026), taking place September 29th – October 2nd at the Cité Internationale Universitaire

Artiva Biotherapeutics Announces Oral Presentation of AlloNK® Clinical Data at the 17th International Symposium on Sjögren’s Disease

Wed, 23 Sep 2026 07:30:00 -0400

Oral presentation to highlight updated clinical data from 11 patients with Sjögren disease (SjD) treated with AlloNK and rituximab, with six months or more of follow-up
SAN DIEGO, Sept. 23, 2026 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (Nasdaq: ARTV) (Artiva), a clinical-stage biotechnology company whose mission is to develop effective, safe and accessible cell therapies for patients with debilitating autoimmune diseases, today announced that updated clinical data will be delivered in an oral presentation at the 17th International Symposium on Sjögren’s Disease (ISSjD 2026), taking place September 29th – October 2nd at the Cité Internationale Universitaire

Artiva Biotherapeutics to Participate in the Stifel 2026 Virtual Immunology and Inflammation Forum

Thu, 17 Sep 2026 08:00:00 -0400

SAN DIEGO, Sept. 17, 2026 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (Nasdaq: ARTV) (Artiva), a clinical-stage biotechnology company whose mission is to develop effective, safe and accessible cell therapies for patients with debilitating autoimmune diseases, today announced that management will participate in a fireside chat at the Stifel 2026 Virtual Immunology and Inflammation Forum on Thursday, September 24, 2026, at 10:00 am EDT.

To access the audio webcast and subsequent archived recording of this and other company presentations, please visit the Investors section of Artiva’s website. The archived audio webcast will

Artiva Biotherapeutics to Participate in the Stifel 2026 Virtual Immunology and Inflammation Forum

Thu, 17 Sep 2026 08:00:00 -0400

SAN DIEGO, Sept. 17, 2026 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (Nasdaq: ARTV) (Artiva), a clinical-stage biotechnology company whose mission is to develop effective, safe and accessible cell therapies for patients with debilitating autoimmune diseases, today announced that management will participate in a fireside chat at the Stifel 2026 Virtual Immunology and Inflammation Forum on Thursday, September 24, 2026, at 10:00 am EDT.

To access the audio webcast and subsequent archived recording of this and other company presentations, please visit the Investors section of Artiva’s website. The archived audio webcast will

Form 4 Artiva Biotherapeutics, For: Sep 15 Filed by: Aslan Fred

Tue, 15 Sep 2026 16:44:00 -0400
si-local-file:///var/storage/secattach/20260915/27065465.html

Form 4 Artiva Biotherapeutics, For: Sep 10 Filed by: Aslan Fred

Mon, 14 Sep 2026 20:07:00 -0400
si-local-file:///var/storage/secattach/20260914/27059752.html

Form 4 Artiva Biotherapeutics, For: Sep 10 Filed by: RA Capital Healthcare Fund LP

Mon, 14 Sep 2026 18:47:00 -0400
si-local-file:///var/storage/secattach/20260914/27059646.html

Form 4 Artiva Biotherapeutics, For: Sep 10 Filed by: Stoppel Laura

Mon, 14 Sep 2026 16:05:00 -0400
si-local-file:///var/storage/secattach/20260914/27058410.html

Form 4 Artiva Biotherapeutics, For: Sep 10 Filed by: HOUGEN ELIZABETH L

Mon, 14 Sep 2026 16:04:00 -0400
si-local-file:///var/storage/secattach/20260914/27058338.html

Form 4 Artiva Biotherapeutics, For: Sep 10 Filed by: Sorg Elaine K.

Mon, 14 Sep 2026 16:04:00 -0400
si-local-file:///var/storage/secattach/20260914/27058341.html

Form 4 Artiva Biotherapeutics, For: Sep 10 Filed by: MOORE ALISON

Mon, 14 Sep 2026 16:03:00 -0400
si-local-file:///var/storage/secattach/20260914/27058317.html